Loading...

Strategies for Organic Drug Synthesis and Design, 2nd Edition

Share Icon

ISBN: 978-0-470-19039-5

October 2008

700 pages

Description
Your Blueprint for Successful Drug Synthesis and Design

Guiding readers through tested-and-proven strategies for designing and conducting drug synthesis, this Second Edition features the latest developments in the field, including new examples of drug synthesis from major pharmaceutical companies. Examples are selected from the multivolume work, titled The Organic Chemistry of Drug Synthesis. This new, expanded edition focuses on the organic chemistry used for drug preparation. Drugs have been selected based on the illustrative value of the chemistry used for their synthesis. Structures in chemical schemes have been carefully drawn to clarify individual reactions.

Brief discussions of medicinal chemistry provide readers with a snapshot of the activity and the mechanism of action of various drugs. Salient principles of drug action are presented in capsule form at appropriate points. In addition, the claimed therapeutic effects of each pharmaceutical agent are noted along with the discussion of its preparation.

Strategies for Organic Drug Synthesis and Design has been updated with a host of new drugs, including drugs that address new therapeutic areas and drugs developed with the use of novel chemistry. These include:

  • Tubulin Inhibitors (Taltobulin)

  • Antimalarial arteflene

  • Neuraminidase Antivirals (Zanamavir, Oseltamavir, and Peramavir)

  • COX-2 Inhibitor NSAIDs (Celecoxib, Cimicoxib, and Valdecoxib)

Written by an experienced and successful author and pharmaceutical scientist, this book meets the needs of the growing community of researchers in pharmaceutical R&D as well as medical professionals who need to understand the design and synthesis of pharmaceutical agents. It is also recommended as a graduate-level medicinal chemistry textbook.

About the Author
Daniel Lednicer, PhD, is the acclaimed author of several books on drug synthesis and discovery. His career has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. He has also served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.